NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
AMEX · CATX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Perspective Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Perspective Therapeutics, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.24. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Perspective Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | -$0.25+10.71% vs estimate | $342.00K+139.94% vs estimate |
|---|
| Q4 2024 | Mar 26, 2025 | -$0.57-119.23% vs estimate | $234.00K-15.61% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.210.0% vs estimate | $369.00K+26.04% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $7.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$13.11-$1.06 (-7.48%)
Novocure Ltd’s quoted price sits in the lower half of its reported 52-week range, 38.88% below the high.
$14.64-$0.22 (-1.48%)
Delcath Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.96% below the high.
$3.86-$0.07 (-1.78%)
TriSalus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.45% below the high.
$2.77-$0.05 (-1.77%)
Sensus Healthcare, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.54% below the high.
$2.85-$0.15 (-4.99%)
iTonic Holdings Ltd.’s quoted price sits in the lower half of its reported 52-week range, 84.51% below the high.
$0.14+$0.01 (+6.87%)
Accuray Incorporated’s quoted price sits in the lower half of its reported 52-week range, 90.41% below the high.
